On Sep 26th - 28th, 3rd Annual Biobank China 2013 (ABC2013) & China Biobanking Summit organized by Shanghai Clinical Research Center (SCRC), Shanghai Consulting & Academic Activities Center for Academicians of Chinese Academy of Engineering(CAE), Shanghai ShenKang Hospital Development Center and Shanghai Engineering Research Center of Biobank, was held successfully in Le Meridien She Shan Shanghai. Over 500 participants from over 10 countries and 20 provinces in China and 150 national and international universities, institutes, hospitals and pharmaceutical companies to exchange thoughts in translational medical research and biobanks, share best practice and experience in construction and management of cohort biobank and clinical disease biobank as well as the quality management and control of the biobank during the conference.
As precious resources for both basic and clinical research, biobanks are the basis of studies on translational medicine. With the support of Ministry of Science and Technology of P.R. China (MST), National Health and Family Planning Commission of P.R. China (NHFPC), Science and Technology Commission, China Biobanking Summit was held on Sep.26th under the major consulting project on Development Strategy of Translational Medicine in China with bio-bank as a key part in the project, initiated by CAE in 2012. The Project, lead by Fan Daiming, Vice President of CAE, and Yang Shengli, Director of Division of Medical and Health Engineering, CAE, is aimed to propose development strategy for translational medical research in China and put forward suggestions for high-level policy makers.
Over 70 experts from renowned biobank projects and institutes such as National Cancer Institute(NCI), Biomedical and Biobanking Resources Research Infrastructure (BBMRI), Public Population Project in Genomics and Society(P3G), Biological and Environmental Repositories (ISBER), Institute of Health and Medical Research(INSERM), Karolinska Institutet (KI),Chinese Academy of Science (CAS) , CAE, leaders from top-level hospitals and government officials exchanged thoughts on forward-looking studies on the development strategy of biobank, proposed corresponding strategies, roadmap for the development of translational medicine suited to real situations in China and put forward suggestions as well as countermeasures for the realization of strategy objectives in China.
Annual Biobank China (ABC), Asia's largest biobank conference and exhibition organized by SCRC and SERCB annually, brings together a global network of professional to foster innovation that will conduce to the better construction and development of biobank. After its 1st and 2nd launch in Shanghai last two years, ABC has gained high recognition in the biobanking field. The 3rd Biobank China 2013 was held on Sep.27th -28th, with focus on the topics of "Translational Medicine & Biobank", "Biobank development for Cohort Studies ", "Development of Diseased-based Biobanks" and "Quality Management System for Biobanking" by considering the current situations of China's biobank construction and the needs of the participants.
The conference was chaired by Professor Shengli Yang, Director of Division of Medical and Health Engineering, CAE, and member of the CAE presidium, Dr Professor Hu Qingli, Senior Adviser Jiaotong University School of Medicine and Director of SCRC IEC, Professor Kurt Zatloukal, Coordinator of BBMRI, Professor Bartha Maria Knoppers, Chairman of P3G Canada. Leading professionals in this area has participated the conference, including Professor Xishan Hao, President of Tianjin Medical University Cancer Institute and Hospital, Professor Lin Li, President of Shanghai Institutes for Biological Sciences, CAS, Dr. Rongxing Gan, Director of SCRC, Professor Weiping Jia, President of 6th People's Hospital affiliated to Shanghai Jiao Tong University, Dr. Guangjun Yu, President of Children's Hospital of Shanghai, Professor Chen-Yang Shen, Chief Executive of Taiwan Biobank, Dr. Jim Vaught, Deputy Director in NCI-BBBR, Professor Bruno Clement, Head of the Inserm Unit "Liver, Metabolisms and Cancer", Professor Georges Dagher, Deputy Director of Clinical Research Dept. INSERM, Professor Andy Zaayenga, President Elect, ISBER, Professor Mark Divers, Director of Karolinska Institutet, Sweden and so on and so forth explored the latest news, shared the best practice and featured the first-hand experience in the management and quality control of the biobanks, discussed the role of biobanks in translational research with top professionals, researchers and leaders.
"Biobanks are pivotal to the development of Personalized Medicine and Translational Medical Research. With the aim to be the pioneer in the globalization of drug development and advocate of the national innovation strategy for clinical research on new drugs, SCRC has been dedicated to biobank development in the past 4 years. " Dr. Rongxing Gan, Director of SCRC said, "We sincerely hope that the conference will serve as a platform for representatives to meet experts and scholars of remarkable fame in China and in other parts of the world, for professionals to exchanges ideas and experience and for organizations and institutes to enhance cooperation in the related field, thus further promoting biobank development."
About Shanghai Clinical Research Center (SCRC)
SCRC is a leading full-service clinical research center in China. Founded under the collaborative framework of the Ministry of Science and Technology and Shanghai Municipality in 2008, SCRC operates as a 3rd-party full-service assessment and resources platform with global standards to make drug development more efficient. With expertise, resources, and network, SCRC endeavors to be a pioneer in the globalization of drug development in China and to be the link between pharmaceutical companies and clinical hospitals. For more information about SCRC, please visit the Website at http://www.scrcnet.org/
